Bristol-Myers Squibb 10-Qquarter ended 2026-06-30

Executive Summary

Bristol Myers Squibb grew Q2 revenue 6% as Eliquis and newer medicines outweighed accelerating generic erosion in mature products. GAAP earnings rose much faster than sales, largely because the prior-year quarter included a $1.51B acquired research and development charge; H1 operating cash flow, however, declined despite higher earnings. Management is investing in launches and early-stage partnerships while targeting productivity savings, but patent challenges, drug-pricing pressure and clinical setbacks could narrow the payoff. For investors, the key test is whether growth products can sustain revenue and cash generation as legacy sales and exclusivity decline.

Key Financial Highlights

• Revenue quality: Q2 gross product sales fell to $18.2B from $22.2B, yet net product sales rose to $12.6B from $11.9B as gross-to-net deductions fell to $5.59B from $10.3B. Lower U.S. rebates, including the effect of Eliquis pricing changes, were therefore a major growth driver alongside demand.
• Earnings quality: H1 acquired in-process R&D fell to $0.094B from $1.70B; lower acquired-intangible amortization also helped GAAP comparisons. These effects are distinct from operating growth. H1 R&D expense nevertheless rose to $5.61B from $4.84B, including $830M of in-process R&D impairments.
• Cash conversion: H1 operating cash flow fell from $5.87B while GAAP net earnings rose; rebates and discounts used $3.14B of cash versus providing $0.254B a year earlier. FCF subtracts $0.652B of capital expenditures from operating cash flow.
• Capital and liquidity: Long-term debt was $42.1B; net debt fell to $31.7B from $34.0B after $1.72B of long-term debt repayments. BMS paid $2.57B in dividends, while shares outstanding rose from ≈2.04B at year-end to ≈2.04B at 6/30/2026, an increase of ≈7M shares; H1 stock-based compensation was $281M. Its $5.0B revolving credit facility was undrawn and extended to January 2031.

Business Developments

Eliquis remained the principal growth engine, with Q2 revenue up 22% to $4.48B. Reblozyl, Breyanzi and Camzyos also expanded, while Opdivo’s decline partly reflected substitution toward Opdivo Qvantig. Conversely, Revlimid revenue fell 49% in Q2 after U.S. generic-license volume restrictions ended, and Pomalyst/Imnovid fell 71%. The resulting portfolio shift increases dependence on continued growth and exclusivity for Eliquis and newer products.

Management’s expanded productivity initiative targets ≈$2.0B of annual savings by the end of 2027, alongside launch investment and pipeline expansion. A Hengrui collaboration covering 13 early-stage assets closed in July: BMS owes $600M in Q3 2026, with later scheduled payments and up to $14.3B of contingent milestones. Existing BioNTech collaboration payments include $2.0B of anniversary payments beginning Q3 2026 through 2028, subject to the agreement remaining in effect. Regulatory progress included application acceptances for iberdomide, mezigdomide, Camzyos and Reblozyl indications, plus new Sotyktu and Opdivo approvals; these provide potential future revenue sources rather than near-term replacements for mature-brand sales.

Risk Assessment

• Patent and generic erosion: Eliquis faces marketed generics in parts of Europe and further patent challenges, while seven generic challengers filed U.S. applications for Camzyos; adverse outcomes could undermine major growth products.
• Pricing and access: Eliquis’s Medicare-negotiated price took effect on 1/1/2026, Pomalyst’s is scheduled for 1/1/2027, and Orencia pricing is set to begin in 2028, adding pressure as rebate and net-price effects have supported recent revenue.
• Development and investment returns: H1 in-process R&D impairments of $830M show that clinical results and portfolio changes can reduce the value of pipeline spending, even as collaboration commitments increase.
• Cash flow and leverage: H1 operating cash flow of $4.50B lagged $5.99B of GAAP net earnings, and long-term debt of $42.1B leaves less flexibility if rebate-related cash outflows persist.
• Litigation: A contingent-value-rights dispute alleges a potential $6.4B Breyanzi-related obligation, which BMS disputes; patent, 340B and tax proceedings add uncertain outcomes.
• Customer concentration: Three U.S. customers accounted for 71% of trade receivables, concentrating collection and commercial exposure.
• Royalty expiry: Disclosed Keytruda and Tecentriq patent-license royalty terms end on 12/31/2026, creating a potential income headwind.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

Strategic Outlook and Investor Actionables

BMS is using growth brands, new indications, partnerships and productivity savings to bridge legacy-product losses. The investment case improves if that transition produces durable operating cash flow—not merely better net pricing or easier GAAP comparisons.

• Portfolio replacement: Track Eliquis, Camzyos, Breyanzi and Reblozyl growth against Revlimid and Pomalyst/Imnovid declines; sustained net portfolio growth would confirm the transition.
• Cash conversion: Compare operating cash flow with GAAP earnings and monitor rebate-related cash movements; renewed divergence would weaken the quality of reported profit.
• Pipeline and exclusivity: Watch upcoming regulatory decisions, Camzyos and Eliquis patent outcomes, and further impairments; approvals without material exclusivity losses would support returns on current investment.